Immuron Travelan® sales continued strong growth
April 10 2024 - 6:00AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and
globally integrated biopharmaceutical company is pleased to
announce record sales (unaudited) of Travelan®, an over-the-counter
immune supplement that targets pathogenic bacteria and the toxins
they produce in the gastrointestinal (GI) tract.
AustraliaSales of Travelan®
increased 250% to AUD $2.7 million FYTD Mar 2024 compared to AUD
$0.8 million FYTD Mar 2023. Sales of Travelan® increased 70% to AUD
$0.9 million Mar 2024 Quarter compared to AUD $0.5 million Mar 2023
Quarter. Excludes sales of Protectyn®.
Consistent with the increase in March 2024
quarter sales, the Australian Bureau of Statistics reported short
term resident returns in January 2024 were 27% higher than January
2023 1.
1. https://www.abs.gov.au/statistics/industry/tourism-and-transport/overseas-arrivals-and-departures-australia/latest-release
USA Sales of Travelan®
increased 35% to AUD $0.8 million FYTD Mar 2024 compared to AUD
$0.6 million FYTD Mar 2023. Sales of Travelan® increased 7% to AUD
$0.3 million Mar 2024 Quarter compared to AUD $0.3 million Mar 2023
Quarter.
Immuron’s experience in the USA follows the
International Trade Administration Total U.S. citizen international
visitor departures from the United States in November 2023 being
11% higher than in November 2022. 2
2. https://www.trade.gov/us-international-air-travel-statistics-i-92-data
Immuron have commenced Travelan® sales in USA
through Walmart.com.
Flavio Palumbo, Chief Commercial Officer said
“We continue to be excited by the strong sales results on
Travelan®. Immuron’s investment to drive awareness of the Travelan®
brand has seen continued strong sales results in Australia. We hope
to get similar growth of the brand as we increase our investment
and distribution in North America during the spring (Mar-May) /
summer (Jun-Aug) vacation peak period.”
This release has been authorised by the
directors of Immuron Limited.
COMPANY
CONTACT:Steven
LydeamoreChief Executive OfficerPh: +61 (0)3 9824
5254info@immuron.com |
|
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases.
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jul 2023 to Jul 2024